Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
Pompe disease is a rare, life-threatening genetic disorder caused by GAA enzyme deficiency, leading to glycogen buildup and muscle cell destruction. It presents on a spectrum, from infantile-onset…
Board-certified nephrologist Blake Shusterman, MD, debunks common kidney health myths. Urinating normally doesn’t guarantee healthy kidneys, and nocturnal urination is often due to aging or other conditions, not…
Ulcerative colitis can cause persistent digestive issues that disrupt daily life. Symptoms may include diarrhea, frequent and urgent bowel movements, blood or pus in stool, severe cramps, nausea,…
Melanoma immunotherapy has a critical limitation: 40 to 60% of patients don’t respond. Arielle Elkrief, MD, discusses an innovative approach targeting the gut microbiome. By using fecal microbiota…
Rheumatoid arthritis isn’t just about joint pain—it can affect multiple organs, leading to complications like heart disease, lung fibrosis, eye conditions, skin vasculitis, and nervous system issues. Micah…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
Jimmy Ruiz, MD, reflects on his career journey in North Carolina and the transformative progress in lung cancer treatment. Early in his career, limited tools like chemotherapy presented…
David Simel, MD, and William Kim, MD, explore renal cell carcinoma in this JAMA Clinical Review podcast. They discuss key insights from the 2019 Nobel Prize research on…
Advances in non-small cell lung cancer (NSCLC) treatment have transformed care from a one-size-fits-all approach in the 1990s to highly personalized regimens today. Treatment now considers actionable mutations…
Faith Davies, MD, shares insights from the IMS 2024 session on high-risk disease, highlighting the debut of a unified high-risk definition. This new framework incorporates 17p deletions, mutations,…
